Immune Thrombocytopenic Purpura - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Immune Thrombocytopenic Purpura - Pipeline Insight, 2021,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Immune Thrombocytopenic Purpura pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Immune Thrombocytopenic Purpura: Overview
Immune Thrombocytopenic Purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune thrombocytopenia, is an autoimmune bleeding disorder characterized by abnormally low levels of blood cells called platelets. The most common symptoms associated with ITP are low platelet count, easy or excessive bruising, superficial bleeding into the skin, mucosal bleeding, blood in urine or stools, and unusual heavy menstrual flow. The risk of developing ITP is more common among young women than men. The diagnosis of ITP is made by physical examination, medical history, and blood test to count the platelets. The tests are done to exclude other causes of thrombocytopenia, including certain medications or disorders that affect the bone marrow and reduce platelet production, such as acute leukemia and aplastic anemia. Treatment for ITP is based on the degree of bleeding occur and the platelet count. First-line treatments for ITP are corticosteroids and intravenous immunoglobulin (IVIG). Second-line treatments include splenectomy, thrombopoietin analogues, and monoclonal antibodies.
'Immune Thrombocytopenic Purpura - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Immune Thrombocytopenic Purpura pipeline landscape is provided which includes the disease overview and Immune Thrombocytopenic Purpura treatment guidelines. The assessment part of the report embraces, in depth Immune Thrombocytopenic Purpura commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune Thrombocytopenic Purpura collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Immune Thrombocytopenic Purpura report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Immune Thrombocytopenic Purpura Emerging Drugs
Further product details are provided in the report……..
Immune Thrombocytopenic Purpura: Therapeutic Assessment
This segment of the report provides insights about the different Immune Thrombocytopenic Purpura drugs segregated based on following parameters that define the scope of the report, such as:
Immune Thrombocytopenic Purpura: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Immune Thrombocytopenic Purpura therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immune Thrombocytopenic Purpura drugs.
Immune Thrombocytopenic Purpura Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Immune Thrombocytopenic Purpura - Pipeline Insight, 2021,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Immune Thrombocytopenic Purpura pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Immune Thrombocytopenic Purpura: Overview
Immune Thrombocytopenic Purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune thrombocytopenia, is an autoimmune bleeding disorder characterized by abnormally low levels of blood cells called platelets. The most common symptoms associated with ITP are low platelet count, easy or excessive bruising, superficial bleeding into the skin, mucosal bleeding, blood in urine or stools, and unusual heavy menstrual flow. The risk of developing ITP is more common among young women than men. The diagnosis of ITP is made by physical examination, medical history, and blood test to count the platelets. The tests are done to exclude other causes of thrombocytopenia, including certain medications or disorders that affect the bone marrow and reduce platelet production, such as acute leukemia and aplastic anemia. Treatment for ITP is based on the degree of bleeding occur and the platelet count. First-line treatments for ITP are corticosteroids and intravenous immunoglobulin (IVIG). Second-line treatments include splenectomy, thrombopoietin analogues, and monoclonal antibodies.
'Immune Thrombocytopenic Purpura - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Immune Thrombocytopenic Purpura pipeline landscape is provided which includes the disease overview and Immune Thrombocytopenic Purpura treatment guidelines. The assessment part of the report embraces, in depth Immune Thrombocytopenic Purpura commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune Thrombocytopenic Purpura collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Immune Thrombocytopenic Purpura R&D. The therapies under development are focused on novel approaches to treat/improve Immune Thrombocytopenic Purpura.
This segment of the Immune Thrombocytopenic Purpura report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Immune Thrombocytopenic Purpura Emerging Drugs
- Rozanolixizumab: UCB
- Mezagitamab: Takeda
Further product details are provided in the report……..
Immune Thrombocytopenic Purpura: Therapeutic Assessment
This segment of the report provides insights about the different Immune Thrombocytopenic Purpura drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Immune Thrombocytopenic Purpura
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Immune Thrombocytopenic Purpura: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Immune Thrombocytopenic Purpura therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immune Thrombocytopenic Purpura drugs.
Immune Thrombocytopenic Purpura Report Insights
- Immune Thrombocytopenic Purpura Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Immune Thrombocytopenic Purpura drugs?
- How many Immune Thrombocytopenic Purpura drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Immune Thrombocytopenic Purpura?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Immune Thrombocytopenic Purpura therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Immune Thrombocytopenic Purpura and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cour Pharmaceutical
- Hutchison MediPharma
- UCB Biopharma
- Takeda
- Genosco
- Sanofi
- Principia Biopharma (Sanofi)
- argenx
- CNP-ITP
- HMPL 523
- Rozanolixizumab
- Mezagitamab
- Cevidoplenib
- SAR-445088
- Rilzabrutinib
- Efgartigimod
Introduction
Executive Summary
Immune Thrombocytopenic Purpura: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Immune Thrombocytopenic Purpura – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Rozanolixizumab: UCB Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Mezagitamab: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
HMPL-523: Hutchison MediPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
CNP-ITP: Cour Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Immune Thrombocytopenic Purpura Key Companies
Immune Thrombocytopenic Purpura Key Products
Immune Thrombocytopenic Purpura- Unmet Needs
Immune Thrombocytopenic Purpura- Market Drivers and Barriers
Immune Thrombocytopenic Purpura- Future Perspectives and Conclusion
Immune Thrombocytopenic Purpura Analyst Views
Appendix
Executive Summary
Immune Thrombocytopenic Purpura: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Immune Thrombocytopenic Purpura – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Rozanolixizumab: UCB Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Mezagitamab: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
HMPL-523: Hutchison MediPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
CNP-ITP: Cour Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Immune Thrombocytopenic Purpura Key Companies
Immune Thrombocytopenic Purpura Key Products
Immune Thrombocytopenic Purpura- Unmet Needs
Immune Thrombocytopenic Purpura- Market Drivers and Barriers
Immune Thrombocytopenic Purpura- Future Perspectives and Conclusion
Immune Thrombocytopenic Purpura Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Immune Thrombocytopenic Purpura
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Immune Thrombocytopenic Purpura
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Immune Thrombocytopenic Purpura
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Immune Thrombocytopenic Purpura
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
